Ethical Aspects of Prodromal Synucleinopathy Prognostic Counseling
Seminars in Neurology · 01.02.2023 · 43 (01) · 166-177
DOI: 10.1055/a-2019-0245 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Seminars in Neurology, erschienen am 01.02.2023. Verfasst von Ambra Stefani und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Medical University of Innsbruck, Innsbruck, Austria. Hauptthemen laut MEDLINE: Synucleinopathies. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 49 Literaturangaben. Gefördert von: NIA NIH HHS, National Institutes of Health.
Abstract (Originalsprache)
Alpha-synucleinopathies can be identified in their prodromal phase, raising several ethical issues. In this review, we first provide definitions of prodromal α-synucleinopathies and discuss the importance of distinguishing between prodromes and risk factors. Next, we discuss the implications of a diagnosis of prodromal α-synucleinopathy and considerations regarding prognostic counseling in both clinical and research settings. We review available data on patient preferences regarding disclosure as well as providers' perspectives. We examine the pros and cons of disclosing a diagnosis of prodromal α-synucleinopathy, taking into consideration the differences between clinical and research settings. Asking about willingness to know in clinical and research settings and the shared decision-making process applied to prognostic counseling is discussed. Concerning research settings, ethical aspects regarding clinical trials are addressed. Availability of direct-to-consumer technologies will likely lead to novel contexts requiring prognostic counseling, and future neuroprotective or neuromodulating treatments may require further considerations on the timing, role, and importance of prognostic counseling. Recommendations on how to address ethical gaps should be a priority for patients, medical professional societies, and research workgroups. Ethical issues must be considered as an integral part of the overall clinical and research approach to prodromal synucleinopathies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Department of Neurology, Medical University of Innsbruck, Innsbruck, Austria.
- Neurological Clinical Research Institute, Massachusetts General Hospital, Harvard University, Boston, Massachusetts.
- Division of General Medical Sciences, Washington University in Saint Louis, Saint Louis, Missouri.
- Department of Neurology, University of Michigan-Ann Arbor, Ann Arbor, Michigan.
- Department of Medical and Surgical Sciences, University of Bologna, Bologna, Emilia-Romagna, Italy.
- Department of Neurology, University of California-Los Angeles, Los Angeles, California.
ORCID-Profile: Ambra Stefani, Erik K St Louis
Förderung
- NIA NIH HHS
- National Institutes of Health
Zitieren
APA
Stefani, A., Mozersky, J., Kotagal, V., Högl, B., Ingravallo, F., Ju, Y. S., Avidan, A., Sharp, R., Videnovic, A., Schenck, C. H., & St Louis, E. K. (2023). Ethical Aspects of Prodromal Synucleinopathy Prognostic Counseling. Seminars in Neurology, 43(01), 166-177. https://doi.org/10.1055/a-2019-0245
Vancouver
Stefani A, Mozersky J, Kotagal V, Högl B, Ingravallo F, Ju YS, et al. Ethical Aspects of Prodromal Synucleinopathy Prognostic Counseling. Seminars in Neurology. 2023;43(01):166-177. doi:10.1055/a-2019-0245
BibTeX
@article{Stefani2023,
author = {Stefani, Ambra and Mozersky, Jessica and Kotagal, Vikas and Högl, Birgit and Ingravallo, Francesca and Ju, Yo-El S and Avidan, Alon and Sharp, Richard and Videnovic, Aleksandar and Schenck, Carlos H and St Louis, Erik K},
title = {Ethical Aspects of Prodromal Synucleinopathy Prognostic Counseling},
journal = {Seminars in Neurology},
year = {2023},
volume = {43},
number = {01},
pages = {166--177},
doi = {10.1055/a-2019-0245}
}
EUVIMED